生物技术公司Aktis Oncology宣布，其核心候选药物AKY-2519的新药临床试验（IND）申请已获得美国食品药品监督管理局（FDA）的正式批准。此次监管绿灯意味着公司可启动针对实体瘤的临床一期试验，标志着其放射性药物研发平台迈入关键验证阶段。
与此同时，Aktis Oncology同步披露了2025财年全年财务数据及业务进展。财报显示，公司通过战略融资活动进一步巩固了资金储备，为后续临床开发提供持续支持。管理层在业务更新中强调，将加速推进管线内多项靶向放射疗法的临床前研究，并拓展与制药企业的合作生态。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.